Jimmy Carter’s Impact on Cancer: The Breast Cancer-Cardiovascular Disease Connection
Liver cells damaged by metabolic issues related to our diets could be a hidden danger, ready to evolve into liver cancer down the line, as a recent study in Nature has pointed out. Viracta Therapeutics made headlines with the halt of a phase II trial involving a combination therapy of nanatinostat and valganciclovir for relapsed/refractory Epstein-Barr virus-positive lymphomas, seeking new ways forward.
Former President Jimmy Carter’s influence on cancer immunotherapy has been long-lasting, as recognized by NBC News. Additionally, stem cell transplants for hematologic malignancies are reportedly on the decline, according to STAT.
An editorial has raised concerns about the use of direct-to-consumer tests for cancer predisposition genes, emphasizing the need for caution in such decisions. Meanwhile, insights from clinical experience with pembrolizumab (Keytruda) for triple-negative breast cancer have opened up new possibilities and considerations for treatment, benefits, and side effects, as reported by the Cleveland Clinic.
In other news, a California oncologist faced legal trouble due to insider trading allegations related to their work on a new cancer drug, leading to a hefty settlement. Cold Spring Harbor Laboratory highlighted a noteworthy “speckle” of evidence that may hold the key to understanding why certain patients respond differently to treatments.
Looking ahead, 10 upcoming clinical studies expected to share data in the first half of 2025 could have far-reaching impacts on cancer and other diseases, as per Biopharma Dive. The next five years are predicted to see significant advancements in drug development, particularly in immuno-oncology and cancer therapeutics, driving innovation in the field.
Notably, individuals with advanced or metastatic breast cancer may also need to consider the potential link to undiagnosed cardiovascular disease, according to findings from the University of Texas MD Anderson Cancer Center.
